Medikine
Company Details
Status: Private
Employees: 11-50
Location:
Menlo Park, California, United States of America
Type:
sample
Technology:
sample
sample
sample
sample
sample
About: Medikine is a biopharmaceutical company with a mission to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a disruptive and versatile drug discovery platform that generates modular “PEPTIKINES” that are smaller in molecular size than, and structurally unrelated to, the natural cytokine proteins they emulate. These PEPTIKINES are readily amenable to further enhancement for desired pharmacokinetics or added pharmacologic features.
Medikine’s lead product candidate MDK-703, which is planned to enter clinical trials in 2022, is an Fc-fusion protein containing an IL-7 PEPTIKINE, which emulates the beneficial properties of IL-7, a cytokine critical to maintaining T cell response. An important feature is its avoidance of the generation of neutralizing antibodies to native IL-7. Medikine has also identified novel PEPTIKINES that activate the IL-2/15βγc receptor and is exploring their use in bispecifics with differentiated profiles, including an IL-7R and IL-2/15Rβγc dual agonist and a cell-targeted IL-2/15Rβγc attenuated agonist.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Medikine | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.